CDSCO Launches Risk-Based Inspections to Strengthen Drug Quality Across India

The Central Drugs Standard Control Organisation (CDSCO) has introduced a risk-based inspection framework for pharmaceutical manufacturing facilities to strengthen drug quality, improve regulatory oversight and ensure greater compliance with Good Manufacturing Practices (GMP). The initiative aims to make inspections more data-driven by prioritising facilities based on potential public health risks.

Under the revised approach, regulatory authorities will focus inspections on manufacturing units with a higher risk profile, considering factors such as previous compliance history, product category, inspection findings and market complaints. Officials believe the new framework will help regulators utilise resources more efficiently while maintaining strict oversight of medicine quality.

Healthcare experts note that risk-based inspections are widely adopted by global regulatory agencies to improve pharmaceutical quality assurance. By identifying high-risk facilities for more frequent inspections, regulators can detect manufacturing deficiencies earlier and reduce the possibility of substandard or unsafe medicines reaching patients.

The CDSCO has also encouraged pharmaceutical manufacturers to strengthen internal quality management systems, documentation practices and production monitoring. Companies are expected to adopt robust quality control measures to ensure compliance with updated regulatory expectations and international manufacturing standards.

Industry experts believe the initiative will enhance India’s reputation as one of the world’s largest producers of generic medicines. Stronger regulatory oversight can improve confidence among domestic consumers and international markets while supporting pharmaceutical exports.

Public health specialists emphasize that maintaining high manufacturing standards is essential for patient safety. Effective regulatory inspections help ensure medicines consistently meet standards for quality, safety and efficacy before they reach hospitals, pharmacies and healthcare providers.

The risk-based inspection model also aligns with the government’s broader objective of modernising pharmaceutical regulation through technology, data analytics and scientific risk assessment. Digital inspection tools and improved compliance monitoring are expected to make regulatory processes more transparent and efficient.

As the new framework is implemented across the country, healthcare authorities expect improved compliance, stronger quality assurance and greater public confidence in India’s pharmaceutical industry. The initiative reinforces the government’s commitment to ensuring safe, effective and high-quality medicines for patients.